Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Pulm Med ; 24(1): 206, 2024 Apr 26.
Article in English | MEDLINE | ID: mdl-38671384

ABSTRACT

BACKGROUND: The Corona Virus Disease 2019 (COVID-19) pandemic has struck globally. Whether the related proteins of retinoic acid (RA) signaling pathway are causally associated with the risk of COVID-19 remains unestablished. We conducted a two-sample Mendelian randomization (MR) study to assess the associations of retinol, retinol binding protein 4 (RBP4), retinol dehydrogenase 16 (RDH16) and cellular retinoic acid binding protein 1 (CRABP1) with COVID-19 in European population. METHODS: The outcome utilized the summary statistics of COVID-19 from the COVID-19 Host Genetics Initiative. The exposure data were obtained from public genome wide association study (GWAS) database. We extracted SNPs from exposure data and outcome data. The inverse variance weighted (IVW), MR-Egger and Wald ratio methods were employed to assess the causal relationship between exposure and outcome. Sensitivity analyses were performed to ensure the validity of the results. RESULTS: The MR estimates showed that retinol was associated with lower COVID-19 susceptibility using IVW (OR: 0.69, 95% CI: 0.53-0.90, P: 0.0065), whereas the associations between retinol and COVID-19 hospitalization or severity were not significant. RBP4 was associated with lower COVID-19 susceptibility using the Wald ratio (OR: 0.83, 95% CI: 0.72-0.95, P: 0.0072). IVW analysis showed RDH16 was associated with increased COVID-19 hospitalization (OR: 1.10, 95% CI: 1.01-1.18, P: 0.0199). CRABP1 was association with lower COVID-19 susceptibility (OR: 0.95, 95% CI: 0.91-0.99, P: 0.0290) using the IVW. CONCLUSIONS: We found evidence of possible causal association of retinol, RBP4, RDH16 and CRABP1 with the susceptibility, hospitalization and severity of COVID-19. Our study defines that retinol is significantly associated with lower COVID-19 susceptibility, which provides a reference for the prevention of COVID-19 with vitamin A supplementation.


Subject(s)
COVID-19 , Genome-Wide Association Study , Retinol-Binding Proteins, Plasma , SARS-CoV-2 , Vitamin A , Humans , COVID-19/genetics , COVID-19/epidemiology , Genetic Predisposition to Disease , Mendelian Randomization Analysis , Polymorphism, Single Nucleotide , Receptors, Retinoic Acid/genetics , Retinol-Binding Proteins, Plasma/metabolism , Retinol-Binding Proteins, Plasma/genetics , SARS-CoV-2/genetics , Vitamin A/blood , Vitamin A/metabolism
2.
Cell Signal ; 114: 110973, 2024 02.
Article in English | MEDLINE | ID: mdl-37981067

ABSTRACT

BACKGROUND: Hypoxia-induced myocardial injury remains to be a huge health issue worldwide. Transient receptor potential vanilloid 4 (TRPV4) is a high-flux Ca2+ channel that is involved in numerous cardiovascular diseases. However, the role of TRPV4 in myocardial hypoxic injury remains unclear. Accordingly, this study aimed to investigate the antiapoptotic activity of TRPV4 inhibition and elucidate the underlying mechanisms in myocardial hypoxic injury. METHODS: The ability of TRPV4 to modulate the endoplasmic reticulum stress (ERS) and apoptosis was assessed in vitro through the administration of the TRPV4 antagonist HC-067047 or the agonist GSK1016790A. Additionally, intracellular Ca2+ concentration was measured by Fluo-4 AM. RESULTS: TRPV4 expression was significantly upregulated in hypoxic H9c2 cells compared with that in normoxic cardiomyocytes, accompanied with increased intracellular Ca2+ levels. Conversely, TRPV4 inhibition alleviated ERS in hypoxic H9c2 cells and prevented apoptosis, whereas TRPV4 agonist exacerbated such events. Furthermore, H9c2 cell apoptosis was attenuated with the administration of 4-PBA, an ERS inhibitor. CONCLUSION: TRPV4 inhibition alleviates hypoxia-induced H9c2 cell apoptosis by mitigating ERS.


Subject(s)
Endoplasmic Reticulum Stress , Myocytes, Cardiac , TRPV Cation Channels , Animals , Rats , Apoptosis , Hypoxia/metabolism , Myocytes, Cardiac/metabolism , TRPV Cation Channels/metabolism
3.
Adv Sci (Weinh) ; 10(32): e2304627, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37767946

ABSTRACT

The regulation of inflammatory response at the site of injury and macrophage immunotherapy is critical for tissue repair. Chiral self-assemblies are one of the most ubiquitous life cues, which is closely related to biological functions, life processes, and even the pathogenesis of diseases. However, the role of supramolecular chiral self-assemblies in the regulation of immune functions in the internal environment of tissues has not been fully explored yet. Herein, 3D supramolecular chiral self-assembling matrixes are prepared to regulate the polarization of macrophages and further enhance the repair of myocardial infarction (MI). Experiments studies show that M-type (left-handed) self-assembling matrixes significantly inhibit inflammation and promote damaged myocardium repair by upregulating M2 macrophage polarization and downstream immune signaling compared with P-type (right-handed), and R-type (non-chirality) self-assembling matrixes. Classical molecular dynamics (MD) simulation demonstrates that M-type self-assembling matrixes display higher stereo-affinity to cellular binding, which enhances the clustering of mechanosensitive integrin ß1 (Itgß1) and activates focal adhesion kinase (FAK) and Rho-associated protein kinase (ROCK), as well as downstream PI3K/Akt1/mTOR signaling axes to promote M2 polarization. This study of designing a 3D chiral self-assembling matrixes microenvironment suitable for regulating the polarization of macrophages will provide devise basis for immunotherapy with biomimetic materials.


Subject(s)
Myocardial Infarction , Humans , Myocardial Infarction/therapy , Myocardial Infarction/metabolism , Macrophages/metabolism , Myocardium/pathology , Signal Transduction , Inflammation/metabolism
4.
Ann Thorac Surg ; 114(4): e275-e277, 2022 10.
Article in English | MEDLINE | ID: mdl-34998736

ABSTRACT

Primary aortoenteric fistula is a rare clinical entity that often has a fatal outcome. It usually arises from an atherosclerotic aneurysm, and induction by abdominal infection is extremely rare. This report presents the case of 54-year-old man with a history of aortic arch replacement and elephant trunk stent implantation 6 years earlier for Stanford type A aortic dissection. At 11 months before his current presentation, he underwent enteroscopy, during which gastrointestinal perforation occurred. Since then, he had experienced episodes of syncope and hemorrhage. Finally, a fistula was found on imaging. Endovascular treatment and digestive tract repair were accomplished. At 13-month follow-up, he had not had a recurrence of hematochezia or fever.


Subject(s)
Aortic Aneurysm, Abdominal , Blood Vessel Prosthesis Implantation , Endovascular Procedures , Intestinal Fistula , Vascular Fistula , Aortic Aneurysm, Abdominal/surgery , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/surgery , Humans , Intestinal Fistula/diagnosis , Intestinal Fistula/etiology , Intestinal Fistula/surgery , Male , Middle Aged , Stents , Treatment Outcome , Vascular Fistula/diagnosis , Vascular Fistula/etiology , Vascular Fistula/surgery , Vascular Surgical Procedures
SELECTION OF CITATIONS
SEARCH DETAIL
...